BioCentury | Dec 8, 2014
Clinical News

Tretinoin gel: Phase II data

...whereas Retin-A Micro significantly increased the number of patients with erythema and dryness from baseline. Phosphagenics...
...not powered for significance. Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX, Laval, Quebec) markets Retin-A Micro. Phosphagenics Ltd....
...TPM/Retinoic Acid , TPM/Tretinoin Business: Dermatology Molecular target: Not applicable Description: Tretinoin formulated with Phosphagenics’...
BioCentury | Jul 21, 2014
Financial News

Phosphagenics proposes private placement

Phosphagenics Ltd. (ASX:POH; OTCQX:PPGNY), Melbourne, Australia Business: Drug delivery, Neurology Date announced: 2014-07-11 Type: Private placement To be raised: Up to A$3 million ($2.8 million) Shares: 37.5 million Price: A$0.08 Shares outstanding prior: 1.2 billion...
BioCentury | Jul 21, 2014
Financial News

Phosphagenics completes private placement

Phosphagenics Ltd. (ASX:POH; OTCQX:PPGNY), Melbourne, Australia Business: Drug delivery, Neurology Date completed: 2014-07-11 Type: Private placement Raised: A$12.2 million ($11.5 million) Shares: 153 million Price: A$0.08 Shares after offering: 1.2 billion Placement agents: Bell Potter...
BioCentury | May 5, 2014
Clinical News

Tretinoin gel: Completed Phase II enrollment

...Micro tretinoin gel microsphere. Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX, Montreal, Quebec) markets Retin-A Micro. Phosphagenics Ltd....
...TPM/Retinoic Acid , TPM/Tretinoin Business: Dermatology Molecular target: Not applicable Description: Tretinoin formulated with Phosphagenics'...
BioCentury | Mar 10, 2014
Company News

Phosphagenics board of directors update

Phosphagenics Ltd. (ASX:POH; OTCQX:PPGNY), Melbourne, Australia Business: Drug delivery, Neurology Appointed: Lawrence Gozlan, chief investment officer of Scientia Capital, as interim chairman WIR Staff Neurology...
BioCentury | Jan 27, 2014
Company News

Phosphagenics, Novartis, Themis Medicare Ltd. sales and marketing update

...gel in India. The product, which uses Targeted Penetration Matrix (TPM) transdermal drug delivery from Phosphagenics...
...supply the product in finished dosage form to Novartis. Themis has exclusive, Indian rights from Phosphagenics...
...TPM gel, in India. Phosphagenics is eligible for royalties on sales of Voveran and Instanac. Phosphagenics Ltd....
BioCentury | Nov 11, 2013
Clinical News

TPM/oxymorphone patch: Phase I data

...Phase I trial showed that all 12 healthy volunteers who received the first application of Phosphagenics'...
...Chadds Ford, Pa.) markets Opana ER, an extended-release opioid analgesic formulated using TIMERx delivery technology. Phosphagenics Ltd....
BioCentury | Apr 15, 2013
Clinical News

TPM/Oxymorphone patch: Phase I data

...An Australian Phase I trial showed that a single patch application of Phosphagenics' TPM/oxymorphone patch "successfully"...
...for the 72-hour duration of the study. The company could not be reached for details. Phosphagenics Ltd....
BioCentury | Apr 8, 2013
Company News

Phosphagenics, Nippon Zoki Pharmaceuticals Co. Ltd. deal

...Following a March 2012 evaluation deal, the companies partnered to develop Phosphagenics' topical TPM/diclofenac to treat...
...Zoki markets topical diclofenac products that do not use the TPM delivery system in Japan. Phosphagenics...
...it will be eligible for milestones, plus royalties (see BioCentury, March 12, 2012). In 2011, Phosphagenics...
BioCentury | Mar 18, 2013
Company News

Hatchtech management update

...Infectious, Agbio/Environmental Hired: Hugh Alsop as CEO, formerly VP of operations and business development at Phosphagenics Ltd....
Items per page:
1 - 10 of 39
BioCentury | Dec 8, 2014
Clinical News

Tretinoin gel: Phase II data

...whereas Retin-A Micro significantly increased the number of patients with erythema and dryness from baseline. Phosphagenics...
...not powered for significance. Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX, Laval, Quebec) markets Retin-A Micro. Phosphagenics Ltd....
...TPM/Retinoic Acid , TPM/Tretinoin Business: Dermatology Molecular target: Not applicable Description: Tretinoin formulated with Phosphagenics’...
BioCentury | Jul 21, 2014
Financial News

Phosphagenics proposes private placement

Phosphagenics Ltd. (ASX:POH; OTCQX:PPGNY), Melbourne, Australia Business: Drug delivery, Neurology Date announced: 2014-07-11 Type: Private placement To be raised: Up to A$3 million ($2.8 million) Shares: 37.5 million Price: A$0.08 Shares outstanding prior: 1.2 billion...
BioCentury | Jul 21, 2014
Financial News

Phosphagenics completes private placement

Phosphagenics Ltd. (ASX:POH; OTCQX:PPGNY), Melbourne, Australia Business: Drug delivery, Neurology Date completed: 2014-07-11 Type: Private placement Raised: A$12.2 million ($11.5 million) Shares: 153 million Price: A$0.08 Shares after offering: 1.2 billion Placement agents: Bell Potter...
BioCentury | May 5, 2014
Clinical News

Tretinoin gel: Completed Phase II enrollment

...Micro tretinoin gel microsphere. Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX, Montreal, Quebec) markets Retin-A Micro. Phosphagenics Ltd....
...TPM/Retinoic Acid , TPM/Tretinoin Business: Dermatology Molecular target: Not applicable Description: Tretinoin formulated with Phosphagenics'...
BioCentury | Mar 10, 2014
Company News

Phosphagenics board of directors update

Phosphagenics Ltd. (ASX:POH; OTCQX:PPGNY), Melbourne, Australia Business: Drug delivery, Neurology Appointed: Lawrence Gozlan, chief investment officer of Scientia Capital, as interim chairman WIR Staff Neurology...
BioCentury | Jan 27, 2014
Company News

Phosphagenics, Novartis, Themis Medicare Ltd. sales and marketing update

...gel in India. The product, which uses Targeted Penetration Matrix (TPM) transdermal drug delivery from Phosphagenics...
...supply the product in finished dosage form to Novartis. Themis has exclusive, Indian rights from Phosphagenics...
...TPM gel, in India. Phosphagenics is eligible for royalties on sales of Voveran and Instanac. Phosphagenics Ltd....
BioCentury | Nov 11, 2013
Clinical News

TPM/oxymorphone patch: Phase I data

...Phase I trial showed that all 12 healthy volunteers who received the first application of Phosphagenics'...
...Chadds Ford, Pa.) markets Opana ER, an extended-release opioid analgesic formulated using TIMERx delivery technology. Phosphagenics Ltd....
BioCentury | Apr 15, 2013
Clinical News

TPM/Oxymorphone patch: Phase I data

...An Australian Phase I trial showed that a single patch application of Phosphagenics' TPM/oxymorphone patch "successfully"...
...for the 72-hour duration of the study. The company could not be reached for details. Phosphagenics Ltd....
BioCentury | Apr 8, 2013
Company News

Phosphagenics, Nippon Zoki Pharmaceuticals Co. Ltd. deal

...Following a March 2012 evaluation deal, the companies partnered to develop Phosphagenics' topical TPM/diclofenac to treat...
...Zoki markets topical diclofenac products that do not use the TPM delivery system in Japan. Phosphagenics...
...it will be eligible for milestones, plus royalties (see BioCentury, March 12, 2012). In 2011, Phosphagenics...
BioCentury | Mar 18, 2013
Company News

Hatchtech management update

...Infectious, Agbio/Environmental Hired: Hugh Alsop as CEO, formerly VP of operations and business development at Phosphagenics Ltd....
Items per page:
1 - 10 of 39